Skip to main content

Sionna Therapeutics, Inc. (SION) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $37.99: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.75; Below-average business quality.

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizer-based therapies for cystic fibrosis. Lead candidates SION-719 (Phase 2a) and SION-451 (Phase 1) target the F508del mutation affecting ~90% of CF patients. As of Dec 31, 2025, the company... Read more

$37.99+15.7% A.UpsideScore 4.7/10#118 of 158 Biotechnology
Stop $35.20Target $43.79(analyst − 13%)A.R:R 1.1:1
Analyst target$50.33+32.5%9 analysts
$43.79our TP
$37.99price
$50.33mean
$24
$63

Sell if holding. Engine safety override at $37.99: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.75; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news boost analyst 0.70, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.

Val7.5Qual1.4Grw5.0Mom3.9Sent8.4Ins3.0Peer4.5Tech6.5Risk1.24.7OVERALL

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Product: SION-719 and SION-451
Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-14.5
Mkt Cap$1.7B
EV/EBITDA-16.5
Profit Mgn0.0%
ROE-31.8%
Rev Growth—
Beta—
DividendNone
Rating analysts16

Quality Signals

Piotroski F2/9

Options Flow

P/C6.75bearish
IV105%elevated
Max Pain$25-34.2% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductSION-719 and SION-451
    10-K Item 1A: 'We are substantially dependent on the success of at least one of our NBD1 stabilizer product candidates, SION-719 and SION-451'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Volatile — 8.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
0.2
Debt Equity
2.2
Short Interest
3.0
Max Pain Risk
3.0
Elevated put/call: 6.75High IV: 105%Above max pain $25Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Current Ratio
5.0
Moat
5.0
Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Ma Position
4.0
Rsi
5.5
Obv
10.0
Volume accumulation (rising OBV)Above 200-day MA
GatesMomentum 3.9<4.5A.R:R 1.1 < 1.5@spotEARNINGS PROXIMITY 5d<=7dInsider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70SEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
50 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $35.10Resistance $46.46

Price Targets

$35
$44
A.Upside+15.3%
A.R:R1.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)
! Momentum score 3.9/10 — below 4.5 minimum
! Reward/Risk 1.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SION stock a buy right now?

Sell if holding. Engine safety override at $37.99: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 14%; Elevated put/call ratio: 6.75; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $35.20. Score 4.7/10, moderate confidence.

What is the SION stock price target?

Take-profit target: $43.79 (+15.7% upside). Prior stop was $35.20. Stop-loss: $35.20.

What are the risks of investing in SION?

Concentration risk — Product: SION-719 and SION-451; Quality below floor (1.4 < 4.0).

Is SION overvalued or undervalued?

Sionna Therapeutics, Inc. trades at a P/E of N/A (forward -14.5). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about SION?

16 analysts cover SION with a consensus score of 4.2/5. Average price target: $50.

What does Sionna Therapeutics, Inc. do?Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizer-based therapies for cystic...

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizer-based therapies for cystic fibrosis. Lead candidates SION-719 (Phase 2a) and SION-451 (Phase 1) target the F508del mutation affecting ~90% of CF patients. As of Dec 31, 2025, the company had $310.3M in cash/securities and no approved products.

Related stocks: NVAX (Novavax, Inc.) · AUPH (Aurinia Pharmaceuticals Inc) · INVA (Innoviva, Inc.) · CPRX (Catalyst Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I)